Literature DB >> 3133120

Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X.

W Reith1, S Satola, C H Sanchez, I Amaldi, B Lisowska-Grospierre, C Griscelli, M R Hadam, B Mach.   

Abstract

The expression of MHC class II genes is tightly regulated. One form of congenital severe combined immunodeficiency (SCID) is characterized by a regulatory defect that precludes expression of HLA class II genes. B lymphocyte cell lines from such SCID patients provide a tool for identifying putative regulatory proteins that bind to class II gene promoters. We have identified three proteins binding to specific segments of the HLA-DRA promoter, two of which interact to form the predominant DNA-protein complex observed. One of these proteins, defined as an X box binding protein (RF-X), is specifically missing in cells from class II deficient SCID patients. We propose that the molecular defect in this congenital HLA class II regulatory deficiency is a lack of RF-X and that this factor plays an important role in the normal regulation of MHC class II gene expression.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3133120     DOI: 10.1016/s0092-8674(88)90389-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  102 in total

1.  Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains.

Authors:  M W Linhoff; J A Harton; D E Cressman; B K Martin; J P Ting
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

2.  CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex.

Authors:  K Masternak; A Muhlethaler-Mottet; J Villard; M Zufferey; V Steimle; W Reith
Journal:  Genes Dev       Date:  2000-05-01       Impact factor: 11.361

3.  Expression of the three human major histocompatibility complex class II isotypes exhibits a differential dependence on the transcription factor RFXAP.

Authors:  M Peretti; J Villard; E Barras; M Zufferey; W Reith
Journal:  Mol Cell Biol       Date:  2001-09       Impact factor: 4.272

4.  CIITA leucine-rich repeats control nuclear localization, in vivo recruitment to the major histocompatibility complex (MHC) class II enhanceosome, and MHC class II gene transactivation.

Authors:  S B Hake; K Masternak; C Kammerbauer; C Janzen; W Reith; V Steimle
Journal:  Mol Cell Biol       Date:  2000-10       Impact factor: 4.272

5.  Associations and interactions between bare lymphocyte syndrome factors.

Authors:  A M DeSandro; U M Nagarajan; J M Boss
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

Review 6.  Gene regulation.

Authors:  D S Latchman
Journal:  BMJ       Date:  1992-04-25

7.  The DNA-binding defect observed in major histocompatibility complex class II regulatory mutants concerns only one member of a family of complexes binding to the X boxes of class II promoters.

Authors:  C Herrero Sanchez; W Reith; P Silacci; B Mach
Journal:  Mol Cell Biol       Date:  1992-09       Impact factor: 4.272

8.  Histone H3K27ac separates active from poised enhancers and predicts developmental state.

Authors:  Menno P Creyghton; Albert W Cheng; G Grant Welstead; Tristan Kooistra; Bryce W Carey; Eveline J Steine; Jacob Hanna; Michael A Lodato; Garrett M Frampton; Phillip A Sharp; Laurie A Boyer; Richard A Young; Rudolf Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-24       Impact factor: 11.205

9.  Transcription analysis of class II human leukocyte antigen genes from normal and immunodeficient B lymphocytes, using polymerase chain reaction.

Authors:  M Bull; A van Hoef; J Gorski
Journal:  Mol Cell Biol       Date:  1990-07       Impact factor: 4.272

10.  Transcriptional control of the invariant chain gene involves promoter and enhancer elements common to and distinct from major histocompatibility complex class II genes.

Authors:  L Zhu; P P Jones
Journal:  Mol Cell Biol       Date:  1990-08       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.